|
|
|
Insider
Information: |
Goeddel David V |
Relationship: |
10% Owner |
City: |
So. San Francisco |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
9 |
|
Direct
Shares |
21,008,913 |
|
Indirect Shares
|
32,725,451 |
|
|
Direct
Value |
$107,224,205 |
|
|
Indirect Value
|
$145,808,454 |
|
|
Total
Shares |
53,734,364 |
|
|
Total
Value |
$253,032,660 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
63
|
4
|
Stock
price went up :
|
24
|
1
|
Stock
price went down : |
39
|
3
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
-0.2%
|
-73.3%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Immune Design Corp. |
IMDZ |
10% Owner |
2016-09-20 |
3,961,942 |
2014-07-29 |
0 |
Premium* |
|
Gritstone Oncology, Inc. |
GRTS |
Managing Partner |
2018-10-02 |
3,102,934 |
2018-10-02 |
0 |
Premium* |
|
Ngm Biopharmaceuticals Inc |
NGM |
Director, 10% Owner |
2024-04-05 |
0 |
2024-04-05 |
1,000 |
Premium* |
|
Rapt Therapeutics, Inc. |
RAPT |
Managing Partner, 10% ... |
2020-09-22 |
5,630,497 |
2019-11-04 |
195,401 |
Premium* |
|
Oric Pharmaceuticals, Inc. |
ORIC |
Managing Partner, 10% ... |
2020-04-28 |
4,768,181 |
|
0 |
Premium* |
|
Revolution Medicines, Inc. |
RVMD |
10% Owner |
2020-11-16 |
2,151,026 |
2020-11-16 |
3,799,202 |
Premium* |
|
Nurix Therapeutics, Inc. |
NRIX |
10% Owner |
2021-05-05 |
1,394,333 |
2021-05-05 |
1,420,954 |
Premium* |
|
Tenaya Therapeutics, Inc. |
TNYA |
|
2021-08-03 |
0 |
2024-02-12 |
22,999,565 |
Premium* |
|
Effector Therapeutics Ord Shs |
EFTR |
10% Owner |
|
0 |
2021-08-25 |
4,309,329 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
145 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 6
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-06-19 |
4 |
B |
$13.91 |
$211,674 |
I/I |
15,214 |
15,852,688 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-06-20 |
4 |
B |
$13.86 |
$213,385 |
I/I |
15,400 |
15,868,088 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-07-15 |
4 |
B |
$13.69 |
$221,547 |
I/I |
16,188 |
15,932,163 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
|
|
2023-11-15 |
4 |
B |
$0.71 |
$11,880 |
I/I |
16,791 |
944,022 |
0.01 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
|
2019-10-09 |
4 |
B |
$10.26 |
$181,848 |
I/I |
17,724 |
16,374,631 |
1.5 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
|
2019-10-10 |
4 |
B |
$10.50 |
$186,102 |
I/I |
17,724 |
16,392,355 |
1.5 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
|
2019-10-11 |
4 |
B |
$10.57 |
$187,343 |
I/I |
17,724 |
16,410,079 |
1.5 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-24 |
4 |
B |
$13.37 |
$238,325 |
I/I |
17,828 |
49,575 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-05-10 |
4 |
B |
$13.85 |
$248,234 |
I/I |
17,923 |
15,709,014 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-20 |
4 |
B |
$13.48 |
$256,533 |
I/I |
19,034 |
48,987 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-07-29 |
4 |
B |
$13.58 |
$260,727 |
I/I |
19,201 |
16,112,872 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-26 |
4 |
B |
$13.49 |
$272,582 |
I/I |
20,201 |
51,671 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-19 |
4 |
B |
$13.25 |
$273,922 |
I/I |
20,666 |
48,359 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-07-12 |
4 |
B |
$13.88 |
$291,765 |
I/I |
21,014 |
15,915,975 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Managing Partner |
|
2020-07-21 |
4 |
OE |
$13.35 |
$320,400 |
D/D |
24,000 |
44,000 |
0 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Managing Partner |
|
2020-09-02 |
4 |
B |
$17.67 |
$487,604 |
D/D |
27,595 |
1,827,025 |
3.92 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-07-24 |
4 |
B |
$13.51 |
$392,502 |
I/I |
29,054 |
16,032,859 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-07-26 |
4 |
B |
$13.59 |
$408,634 |
I/I |
30,059 |
16,093,671 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-07-25 |
4 |
B |
$13.37 |
$411,294 |
I/I |
30,753 |
16,063,612 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-07-22 |
4 |
B |
$13.54 |
$416,337 |
I/I |
30,760 |
15,973,045 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-07-23 |
4 |
B |
$13.35 |
$410,535 |
I/I |
30,760 |
16,003,805 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-10 |
4 |
B |
$11.36 |
$355,283 |
I/I |
31,265 |
31,818 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-16 |
4 |
B |
$12.90 |
$427,891 |
I/I |
33,166 |
42,671 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-10-15 |
4 |
B |
$10.31 |
$342,292 |
I/I |
33,200 |
16,478,179 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2020-02-27 |
4 |
B |
$17.91 |
$607,077 |
I/I |
33,896 |
16,693,376 |
2.25 |
% |
|
145 Records found
|
|
Page 3 of 6 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|